0001209191-23-010120.txt : 20230216
0001209191-23-010120.hdr.sgml : 20230216
20230216170015
ACCESSION NUMBER: 0001209191-23-010120
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230214
FILED AS OF DATE: 20230216
DATE AS OF CHANGE: 20230216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ashe Andrew D.
CENTRAL INDEX KEY: 0001573163
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 23639226
MAIL ADDRESS:
STREET 1: C/O DYAX CORP.
STREET 2: 55 NETWORK DRIVE
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-14
0
0001840574
Verve Therapeutics, Inc.
VERV
0001573163
Ashe Andrew D.
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
BOSTON
MA
02215
0
1
0
0
See Remarks
Stock Option (right to buy)
21.76
2023-02-14
4
A
0
182800
0.00
A
2033-02-13
Common Stock
182800
182800
D
The option was granted on February 14, 2023. 25% of the shares underlying the option will vest on February 14, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2027.
President, Chief Operating Officer and General Counsel
/s/ Andrew Ashe
2023-02-16